Gliese A, Busch C-J, Knecht R
Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Kopf-Hals-Chirurgie und Onkologie, Universitäres Cancer Center Hamburg, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland.
HNO. 2014 Nov;62(11):781-6. doi: 10.1007/s00106-014-2926-1.
The two available options for primary radiochemotherapy (RCT) of locally advanced head and neck squamous cell carcinoma are discussed in the current study: concomitant and sequential RCT. At the annual meeting of the American Society of Clinical Oncology (ASCO) 2014, results of current trials on the primary nonsurgical therapy of locally advanced head and neck tumors were presented. A selection of the most important trials will be summarized in this article. Studies including cisplatin-based RCT as standard therapy for locally advanced head and neck tumors, alternatives for cisplatin, combination with targeted therapy, application of the epidermal growth factor receptor (EGFR) antibody cetuximab and the comparison of concomitant and sequential RCT are discussed. The first completely recruited phase III trial comparing concomitant and sequential RCT will also be presented.
本研究讨论了局部晚期头颈部鳞状细胞癌原发性放化疗（RCT）的两种可行方案：同步放化疗和序贯放化疗。在2014年美国临床肿瘤学会（ASCO）年会上，公布了当前局部晚期头颈部肿瘤非手术治疗试验的结果。本文将总结一些最重要的试验。讨论的研究包括以顺铂为基础的RCT作为局部晚期头颈部肿瘤的标准治疗、顺铂的替代方案、与靶向治疗的联合应用、表皮生长因子受体（EGFR）抗体西妥昔单抗的应用以及同步放化疗和序贯放化疗的比较。还将介绍首个比较同步放化疗和序贯放化疗的完全入组的III期试验。
